Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry - Scorecard - MDSpire

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

  • By

  • Hyungwoo Cho

  • Koji Kato

  • Jason Yongsheng Chan

  • Kim Dajung

  • Haiwen Huang

  • Qingqing Cai

  • Tongyu Lin

  • Udomsak Bunworasate

  • Sen-Mui Tan

  • Ka-Won Kang

  • Jae-Yong Kwak

  • Tsai-Yun Chen

  • Jeong-Ok Lee

  • Seong Hyun Jeong

  • Young Rok Do

  • Esther Chan

  • Hye Jin Kang

  • Hyeon-Seok Eom

  • Sung Yong Oh

  • Youngil Koh

  • Hyo Jung Kim

  • Se-Hyung Kim

  • Jong Ho Won

  • Young Hoon Park

  • Deok Hwan Yang

  • Soo Chin Ng

  • Jae-Cheol Jo

  • Hilman Tadjoedin

  • Anna Mira Lubis

  • Noorwati Sutandyo

  • Tsuyoshi Muta

  • Ken Takase

  • Dok Hyun Yoon

  • Won Seog Kim

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Advancements in Treatment and Survival Outcomes of Consolidation Therapies for Mantle Cell Lymphoma: Findings from a Real-World Registry in the Asia-Pacific Region

At a Glance

CategoryDetail
Condition
Key MechanismsIntensive cytarabine-based regimens followed by autologous stem cell transplantation (ASCT) and rituximab maintenance therapy.
Target Population
Care Setting

Key Highlights

  • Median age at diagnosis was 62 years; 75.1% were male.
  • 86.8% received rituximab-based regimens as first-line therapy.
  • Upfront ASCT utilization increased from 13.8% in 2013 to 40.0% in 2020.
  • Rituximab maintenance therapy usage increased to 28.0% by 2020.

Guideline-Based Recommendations

Diagnosis

  • Utilize the MCL International Prognostic Index (MIPI) for risk stratification.

Management

  • Consider intensive cytarabine-based regimens followed by ASCT for younger or fit patients.
  • Implement rituximab maintenance therapy for eligible patients.

Monitoring & Follow-up

  • Regularly assess patient response to first-line therapy and eligibility for ASCT and maintenance.

Risks

  • Consider patient age, performance status, and comorbidities when determining treatment strategies.

Patient & Prescribing Data

642 patients with newly diagnosed MCL from January 2008 to November 2020.

R-CHOP or R-CHOP-like regimens were predominant but declined over time; BR became the most common regimen by 2020.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

    • by Hyungwoo Cho, Koji Kato, Jason Yongsheng Chan, Kim Dajung, Haiwen Huang, Qingqing Cai, Tongyu Lin, Udomsak Bunworasate, Sen-Mui Tan, Ka-Won Kang, Jae-Yong Kwak, Tsai-Yun Chen, Jeong-Ok Lee, Seong Hyun Jeong, Young Rok Do, Esther Chan, Hye Jin Kang, Hyeon-Seok Eom, Sung Yong Oh, Youngil Koh, Hyo Jung Kim, Se-Hyung Kim, Jong Ho Won, Young Hoon Park, Deok Hwan Yang, Soo Chin Ng, Jae-Cheol Jo, Hilman Tadjoedin, Anna Mira Lubis, Noorwati Sutandyo, Tsuyoshi Muta, Ken Takase, Dok Hyun Yoon, Won Seog Kim

    • May 29, 2026

    Related Content

    Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

    Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

    Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2